Navigation Links
Bio-AMD, Inc.; DSR Commercial Refinement, Prospective Patent Applications

LONDON, Dec. 21, 2011 /PRNewswire/ -- Bio-AMD, Inc. ("Bio-AMD" or the "Company) (OTCBB: BIAD) today announces an update on progress on a Digital Strip Reader ("DSR"), one of the three core Point Of Care ("POC") diagnostic device technologies owned by its 63% owned subsidiary, Bio-AMD Limited.

The Company believes that DSR can be applied to semi-quantitatively read lateral flow test strips for multiple diagnostics, particularly in established pregnancy and women's wellbeing tests market, where there is a shift toward digital devices.  Bio-AMD Limited is developing strategic relationships in the cardiovascular, cholesterol and infectious diseases markets where there are clear commercial and medical advantages to quick, accurate and affordable diagnosis results, without the need for laboratory intervention.

In response to discussions with potential commercial partners Bio-AMD Limited has further developed its single test DSR device to include a proprietary sensor array element. This improves sensor sensitivity, reliability and output matching. It also offers a 70% cost of manufacture saving and a wider universe of potential component suppliers, compared to previous designs. Bio-AMD Limited expects to make a patent application for this technology.

Bio-AMD Limited has also further refined its multi test DSR technology to address specific commercial needs.  This now offers an up to 40% cost of manufacture saving and is more environmentally friendly, with very low power requirements, compared to previous designs.  An increased number of common components in the multi test device also allow further economies of scale across multiple DSR applications. This is believed to precisely address the needs of key commercial players seeking to licence this type of technology. Bio-AMD Limited intends to make a further patent application for its multi-test cartridge/reader mechanism.

The Company is confident that Bio-AMD Limited has every prospect of entering into commercial development and licencing agreements(s) for DSR in 2012. Manufacturers and distributors not yet in discussion with Bio-AMD Limited may contact the company at

About Bio-AMD, Inc.

Bio-AMD has two majority owned UK subsidiaries: Bio-AMD Limited, a technology developer for medical diagnostic devices; and the WDX Organisation Ltd, the owner of the Wocu™, a global currency data reference source for application in financial markets. (

To find out more about Bio-AMD (OTCBB: BIAD), visit our websites at

Forward-Looking Statements

Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties.  Forward-looking statements can often be identified by words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import.  Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management.  Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company.  Readers are cautioned not to place undue reliance on such forward-looking statements.  Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2010 filed on March 23, 2011.  Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.


Bio-AMD, Inc.


Tom Barr, CEO


+44 (0)8445 861 910

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Raises Target Price From $4.40 to $6.50
2. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
3. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
4. Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
5. Nucletron Announces Market Release of First Commercially Available Software to Review and Share Dicom-Based Treatment Plans for Radiotherapy
6. CMS, Inc., an Elekta Company, Announces Commercial Availability of Focal4D(TM)
7. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
8. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
9. Samaritan Partners Forgetful Rat Model to Taconic to Commercialize
10. POET Receives Additional $76 Million in Federal Funding For Commercialization of Cellulosic Ethanol
11. Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... Conference in New York on Wednesday, December ... Helen Torley , president and CEO, will provide a corporate overview. ... New York at 1:00 p.m. ET/10:00 a.m. PT . ... investor relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... Global, Inc., a worldwide provider of clinical research services headquartered in ... company has set a new quarterly earnings record in Q3 of ... for Q3 of 2014 to Q3 of 2015.   ... with the establishment of an Asia-Pacific office ... Kingdom and Mexico , with the ...
(Date:11/24/2015)... , November 24, 2015 ... recent market research report released by Transparency Market Research, ... expand at a CAGR of 17.5% during the period ... Testing Market - Global Industry Analysis, Size, Volume, Share, ... global non-invasive prenatal testing market to reach a valuation ...
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier of easy-to-use ... promoted Melanie Aregger to serve as Chief Operating Officer. , Having joined ... management team and was promoted to Head of InSphero Diagnostics in 2014. ...
Breaking Biology Technology:
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced expansion of its TDDI ... touch controller and display driver integration (TDDI) ... smartphones. These new TDDI products add to the ... resolution), TD4302 (WQHD resolution), and TD4322 (FHD resolution) ...
(Date:11/12/2015)... LONDON , Nov. 11, 2015   ... and reliable analytical tools has been paving the ... and qualitative determination of discrete analytes in clinical, ... sensors are being predominantly used in medical applications, ... and environmental sectors due to continuous emphasis on ...
(Date:11/10/2015)... About signature verification Signature ... identify and verify the identity of an individual ... secure and accurate method of authentication and is ... because each individual,s signature is highly unique. Signature ... signature of an individual is compared and matched ...
Breaking Biology News(10 mins):